If you are:
FDB Contraindicated or Not Recommended: FETAL DEATH/MORBIDITY W/USE IN 2ND & 3RD TRIMESTER, STOP WHEN PREGNANCY DETECTED
Possibly Safe: NOT RECOMMENDED IN PRE-ECLAMPSIA AND OTHER PREGNANCY-INDUCED HYPERTENSION.
FDB Only When Necessary: UNCONTROLLED HTN CAN RESULT IN INCREASED MATERNAL/FETAL MORBIDITY AND MORTALITY
Precaution: INSUFFICIENT DATA AVAIL; CONSIDER MATERNAL TREATMENT BENEFIT VS INFANT RISK
Precaution: CAUTION ADVISED; SERIOUS ADVERSE EFFECTS POSSIBLE
Precaution: LIMITED AMOUNTS EXCRETED WITH NO KNOWN ADVERSE EFFECTS IN INFANT.
An adult over 60:
management or monitoring precaution: Cardiovascular-Increased sensitivity to effects on blood pressure. Metabolic-more likely to develop hypokalemia or hypomagnesemia. Endocrine-May worsen glucose control in diabetics. Renal-Not effective with CrCL < 30mL/min.
management or monitoring precaution: General-Not recommended as first line therapy in the elderly. Cardiovascular-Start at 2.5 mg/day and slowly titrate upward. Peripheral edema may be common. Lower drug clearance may result in increased sensitivity to blood pressure lowering effects. Gastrointestinal-May cause or worsen pre-existing constipation.
Giving aliskiren 300 mg-amlodipine 10 mg-hydrochlorothiazide 25 mg tablet to a child under 12:
management or monitoring precaution: No safety and efficacy data for age < 6 years.
management or monitoring precaution: Potential risk of increased drug exposure and toxicity. Safety and efficacy not established in pediatrics.